The "famous pairs" in Laboratory Medicine;Le "coppie celebri" in Medicina di Laboratorio

Biochimica Clinica

Volumn 38, Issue 4, 2014, Pages 307-313

  Castaldo, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AMINOTRANSFERASE; AMYLASE; ANTISTREPTOLYSIN; C REACTIVE PROTEIN; CREATININE; GLIADIN ANTIBODY; RHEUMATOID FACTOR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ANTIBODY TITER; BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LABORATORY; LABORATORY TEST; MEDICINE; NOTE; PARTIAL THROMBOPLASTIN TIME; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PROTHROMBIN TIME; UREA BLOOD LEVEL;

EID: 84906500019     PISSN: 03930564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (56)

1. Castaldo G, Lembo F, Tomaiuolo R. Molecular diagnostics: between chips and customized medicine. Clin Chem Lab Med 2010;48:973-82.
2. Ahluwalia J, Sharma P, Das R. Laboratory screening of thrombophilia testing requisitions for adequacy/appropriateness and reduced abnormal results. Int J Lab Hematol 2012 Jun 18. doi: 10.1111/j.1751-553X.2012.01444.x. [Epub ahead of print]
3. Plebani M, Lippi G. Closing the brain-to-brain loop in laboratory testing. Clin Chem Lab Med 2011;49:1131-3.
4. Plebani M. Evaluating laboratory diagnostic tests and translational research. Clin Chem Lab Med 2010;48:983-8.
5. Prat G, Lefevre M, Nowak E, et al. Impact of clinical guidelines to improve appropriateness of laboratory tests and chest radiographs. Intensive Care Med 2009;35:1047-53.
6. Salinas M, Lopez-Garrigos M, Uris J: on behalf of the Pilot Group of the Appropriate Utilization of Laboratory Tests Working Group. Differences in laboratory requesting patterns in emergency department in Spain. Ann Clin Biochem 2013;50:353-9.
7. Sato D, Fushimi K. Impact of teaching intensity and academic status on medical resource utilization by teaching hospitals in Japan. Health Policy 2012;108:86-92.
8. Sciacovelli L, Zardo L, Secchiero S, et al. Interpretative comments and reference ranges in EQA programs as a tool for improving laboratory appropriateness and effectiveness. Clin Chim Acta 2003;333:209-19. (Pubitemid 36775368)
9. Camerotto A, Carmignoto F. L'utilizzo di note informative per gli esami di laboratorio: uno strumento per l'appropriatezza e per il risparmio di risorse nella medicina di laboratorio. Biochim Clin 2005;29:433-45.
10. Delanaye P, Ebert N. Assessment of kidney function: estimating GFR in children. Nat Rev Nephrol 2012;8:503-4.
11. Weinert LS, Camargo EG, Soares AA, et al. Glomerular filtration rate estimation: performance of serum cystatin C-based prediction equations. Clin Chem Lab Med 2011;49:1761-71.
12. Inker LA, Okparavero A. Cystatin C as a marker of glomerular filtration rate: prostects and limitations. Curr Opin Neprhrol Hypertens 2011;20:631-9.
13. Milani P, Graziani MS, Merlini G. Marcatori biochimici di danno renale acuto. Biochim Clin 2010;34:585-90.
14. Fassett RG, Venuthurupalli SK, Gobe GC, et al. Biomarkers in chronic kidney disease: a review. Kidney Intern 2011;806-21.
15. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 2012;51:5-9.
16. Geerts I, De Vos N, Frans J, et al. The clinical-diagnostic role of antistreptolysin O antibodies. Acta Clin Belg 2011;66:410-5.
17. Kaplan EL, Rothermel CD, Johnson DR. Antistreptolysin O and anti-deoxyribonuclease B titers: normal values for children ages 2 to 12 in the United States. Pediatrics 1998;101:86-8. (Pubitemid 28030329)
18. Mirabel M, Jouven X, Sidi D, et al. What is the remaining burden of rheumatic heart disease worldwide? Rev Prat 2013;63:8-10.
19. Longo G. Domande e risposte. Medico e Bambino 2001;8:550.
20. De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis: the transaminase serum activities. Clin Chim Acta 1957;369:148-52.
21. Nyblom H, Berggren U, Balldin J, et al. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004;39:336-9.
22. Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93:44-8. (Pubitemid 29065511)
23. Sacchetti L, Castaldo G, Salvatore F. The gamma-glutamyltransferase isoenzyme pattern in serum as a signal discriminating between hepatobiliary diseases, including neoplasias. Clin Chem 1988;34:352-5. (Pubitemid 18064989)
24. Fornaciari I, Clerico A, Emdin M, et al. Forme molecolari della gamma-glutamiltransferasi: caratteristiche e biogenesi. Biochim Clin 2012;36:112-20.
25. Bianchi V, Pacifici R, Palmi I, et al. Transferrina carboidrato-carente (CDT): strategie analitiche ed interpretative. Biochim Clin 2010;34:128-38.
26. Topic A, Djukic M. Diagnostic characteristics and application of alcohol biomarkers. Clin Lab 2013;59:233-45.
27. Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47:1696-700. (Pubitemid 32781585)
28. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013;158:807-20.
29. Castaldo G, Oriani G, Lofrano MM, et al. Differential diagnosis between hepatocellular carcinoma and cirrhosis through a discriminant function based on results from serum analytes. Clin Chem 1996;42:1263-9. (Pubitemid 26260348)
30. Castaldo G, Calcagno G, Sibillo R, et al. Quantitative analysis of aldolase A mRNA in liver discriminates between hepatocellular carcinoma and cirrhosis. Clin Chem 2000;46:901-6. (Pubitemid 30461258)
31. Raymond FD, Fortunato G, Moss DW, et al. Inositol-specific phospholipase D activity in health and disease. Clin Sci 1994;86:447-51. (Pubitemid 24137319)
32. Lepper PM, Dufour JF. Elevated transaminases - what to do if everything was done? Praxis 2009;98:330-4.
33. Volta U, Villanacci V. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol 2011;8:96-102.
34. Pietrangelo A. Inherited metabolic disease of the liver. Curr Opin Gastroenterol 2009;25:209-14.
35. Castaldo G, Rippa E, Salvatore D, et al. Severe liver impairment in a cystic fibrosis-affected child homozygous for the G542X mutation. Am J Med Genet 1997;69:155-8. (Pubitemid 27113735)
36. Castaldo G, Fuccio A, Salvatore D, et al. Liver expression in cystic fibrosis could be modulated by genetic factors different from the Cystic Fibrosis Transmembrane Regulator genotype. Am J Med Genet 2001;98:294-7. (Pubitemid 32126005)
37. Amato F, Bellia C, Cardillo G, et al. Extensive molecular analysis of patients bearing CFTR-related disorders. J Mol Diagn 2012;14:81-9.
38. Gion M, Trevisol C, Pregno S, et al., a nome dei Gruppi e Comitati di Progetto della Guida. Guida all'uso dei biomarcatori in oncologia: i marcatori nelle diverse neoplasie - Parte I. Biochim Clin 2011;35:394-404.
39. Gion M, Trevisol C, Pregno S, et al., a nome dei Gruppi e Comitati di Progetto della Guida. Guida all'uso dei biomarcatori in oncologia: i marcatori nelle diverse neoplasie - Parte II. Biochim Clin 2011;35:465-73.
40. Nakagawa K, Koike S, Matsumura H, et al. Alpha-fetoprotein producing rectal cancer. Gan To Kagaku Ryoho 2012;39:671-4.
41. Gion M, Trevisol C, Pregno S, et al., a nome dei Gruppi e Comitati di Progetto della Guida. Guida all'uso clinico dei biomarcatori in oncologia: le prospettive. Biochim Clin 2012;36:40-5.
42. Dolci A, Scapellato L, Panteghini M. Valutazione dell'efficacia di raccomandazioni aziendali sulle strategie per l'impiego ottimale dei biomarcatori in oncologia ad un anno dalla loro introduzione. Biochim Clin 2008;32:181-5.
43. Bourgey M, Calcagno G, Tinto N, et al. HLA related genetic risk for coeliac disease. Gut 2007;56:1054-9. (Pubitemid 47123232)
44. Husby S, Koletzko S, Korpanay-Szabo JR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136-60.
45. Licata A, Randazzo C, Cappello M, et al. Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. J Clin Gastroenterol 2012;46:504-8.
46. Di Mario F, Moussa AM, Caruana P, et al. 'Serological biopsy' in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection. Scand J Gastroenterol 2003;38:1223-7. (Pubitemid 38096079)
47. Dolci A, Vernocchi A per il Gruppo di Studio SIBioC Proteine. Aspetti metodologici nella ricerca e caratterizzazione delle componenti monoclonali nel siero. Biochim Clin 2012;36:84-9.
48. Merlini. Perchè è importante identificare e segnalare le piccole componenti monoclonali. Biochim Clin 2012;36:25-8.
49. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121-7.
50. Solomon S, Whitcomb DC. Genetics of pancreatitis: an update for clinicians and genetic counselors. Curr Gastroenterol Rep 2012;14:112-7.
51. Hamoir C, Pepermans X, Piessevaux H, et al. Clinical and morphological characteristics of sporadic genetically determined pancreatitis as compared toidiopathic pancreatitis: higher risk of pancreatic cancer in CFTR variants. Digestion 2013;87:229-39.
52. Panteghini M, Pagani M. Isoenzimi dell'analisi: laboratorio e clinica. Biochim Clin 2000;24:421-30.
53. Panteghini M, Ceriotti F, Franzini C, et al. Raccomandazione per l'impiego routinario della determinazione dell'isoenzima pancreatico dell'amilasi in sostituzione dell'amilasi totale nella diagnosi e nel monitoraggio della patologia pancreatica. Biochim Clin 2001;25:277-82.
54. Panteghini M. Laboratory evaluation of pancreatic diseases. Biochim Clin 2010;34:19-25.
55. Lang T. The Association for Clinical Biochemistry and Laboratory Medicine. National minimum re-testing interval project. Prepared for the Clinical Practice Group of the ACB and supported by the Royal College of Pathologists, 2013:1-36.
56. Price CP, Christenson RH. Ask the right question: a critical step for practing evidence-based laboratory medicine. Ann Clin Biochem 2013;50:306-14.